Abstract
The process for development of these consensus Australasian antifungal guidelines for use in adult patients with haematological malignancy is described. New features included, how the guidelines should be applied, the risk assessment tool used and the grading system for evidence and strength of recommendation are discussed.
Publication types
-
Introductory Journal Article
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antifungal Agents / therapeutic use*
-
Humans
-
Mycoses / complications*
-
Mycoses / drug therapy*
-
Neoplasms / complications*
-
Neutropenia / complications*
-
Opportunistic Infections / complications*
-
Opportunistic Infections / drug therapy*
-
Practice Guidelines as Topic